DK1401502T3 - Farmaceutisk formulering, der omfatter iota-carrageenan og mindst én neutral geldannende polymer - Google Patents

Farmaceutisk formulering, der omfatter iota-carrageenan og mindst én neutral geldannende polymer

Info

Publication number
DK1401502T3
DK1401502T3 DK02744027T DK02744027T DK1401502T3 DK 1401502 T3 DK1401502 T3 DK 1401502T3 DK 02744027 T DK02744027 T DK 02744027T DK 02744027 T DK02744027 T DK 02744027T DK 1401502 T3 DK1401502 T3 DK 1401502T3
Authority
DK
Denmark
Prior art keywords
iota
carrageenan
pharmaceutical formulation
gelling polymer
neutral gelling
Prior art date
Application number
DK02744027T
Other languages
Danish (da)
English (en)
Inventor
Helena Gustafsson
Khoo Cynthia Gaik-Lim
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0102069A external-priority patent/SE0102069D0/xx
Priority claimed from SE0201660A external-priority patent/SE0201660D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK1401502T3 publication Critical patent/DK1401502T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
DK02744027T 2001-06-21 2002-06-19 Farmaceutisk formulering, der omfatter iota-carrageenan og mindst én neutral geldannende polymer DK1401502T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0102069A SE0102069D0 (sv) 2001-06-21 2001-06-21 Pharmaceutical formulation
SE0104049 2001-11-30
SE0201660A SE0201660D0 (sv) 2002-05-31 2002-05-31 Pharmaceutical formulation

Publications (1)

Publication Number Publication Date
DK1401502T3 true DK1401502T3 (da) 2006-04-10

Family

ID=27354711

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02744027T DK1401502T3 (da) 2001-06-21 2002-06-19 Farmaceutisk formulering, der omfatter iota-carrageenan og mindst én neutral geldannende polymer

Country Status (31)

Country Link
US (1) US7700582B2 (fr)
EP (1) EP1401502B1 (fr)
JP (1) JP2005501024A (fr)
KR (1) KR20040011542A (fr)
CN (1) CN1518462A (fr)
AR (1) AR034517A1 (fr)
AT (1) ATE314093T1 (fr)
AU (1) AU2002345463B2 (fr)
BG (1) BG108516A (fr)
BR (1) BR0210489A (fr)
CA (1) CA2450449A1 (fr)
CO (1) CO5550466A2 (fr)
CZ (1) CZ299859B6 (fr)
DE (1) DE60208369T2 (fr)
DK (1) DK1401502T3 (fr)
EE (1) EE200400028A (fr)
ES (1) ES2254699T3 (fr)
HU (1) HUP0400850A3 (fr)
IL (2) IL159217A0 (fr)
IS (1) IS2347B (fr)
MX (1) MXPA03011546A (fr)
MY (1) MY130332A (fr)
NO (1) NO20035627D0 (fr)
NZ (1) NZ530086A (fr)
PL (1) PL366432A1 (fr)
RU (1) RU2323006C2 (fr)
SI (1) SI1401502T1 (fr)
SK (1) SK286238B6 (fr)
UA (1) UA77959C2 (fr)
WO (1) WO2003000293A1 (fr)
ZA (1) ZA200309316B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
AR035216A1 (es) * 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
KR101016619B1 (ko) * 2001-11-13 2011-02-23 아스텔라스세이야쿠 가부시키가이샤 용해성 약물 지속 방출 시스템
SE0201659D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab Modified release pharmaceutical formulation
SE0201661D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab New salts
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
US7442387B2 (en) * 2003-03-06 2008-10-28 Astellas Pharma Inc. Pharmaceutical composition for controlled release of active substances and manufacturing method thereof
US20050042289A1 (en) * 2003-04-29 2005-02-24 Yamanouchi Pharma Technologies, Inc. Tablets and methods for modified release of hydrophylic and other active agents
US7781424B2 (en) * 2003-05-27 2010-08-24 Astrazeneca Ab Modified release pharmaceutical formulation
SE0303220D0 (sv) * 2003-11-28 2003-11-28 Astrazeneca Ab New process
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
US20060105039A1 (en) 2004-10-21 2006-05-18 Jin-Wang Lai Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
WO2006046954A1 (fr) * 2004-10-26 2006-05-04 Mcneil-Ppc, Inc. Composition polymere a liberation en rafales et formes posologiques comprenant ladite composition
US9161918B2 (en) * 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
TW200827336A (en) 2006-12-06 2008-07-01 Astrazeneca Ab New crystalline forms
CA2677201C (fr) * 2007-02-01 2015-11-17 Takeda Pharmaceutical Company Limited Preparation solide comprenant de alogliptine et de la pioglitazone
TW200900033A (en) * 2007-06-21 2009-01-01 Wen-Qing Li Automatic brewing machine
US20090061000A1 (en) * 2007-08-31 2009-03-05 Astrazeneca Ab Pharmaceutical formulation use 030
PL2262486T3 (pl) 2008-08-01 2013-06-28 Krka Tovarna Zdravil D D Novo Mesto Kompozycja kwetiapiny
TWI478733B (zh) * 2009-05-13 2015-04-01 Wyeth Llc 突釋藥物釋放組合物
CA2782285A1 (fr) 2009-12-02 2011-06-09 Luigi Mapelli Microcapsules de fexofenadine et compositions les contenant

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU178398B (en) 1979-06-12 1982-04-28 Gyogyszerkutato Intezet Process for producing new agmatine derivatives of activity against haemagglutination
JPS57149217A (en) * 1981-03-11 1982-09-14 Kaken Pharmaceut Co Ltd Slow-releasing pharmaceutical preparation
HU192646B (en) 1984-12-21 1987-06-29 Gyogyszerkutato Intezet Process for preparing new n-alkyl-peptide aldehydes
ZA86746B (en) 1985-02-04 1986-09-24 Merrell Dow Pharma Novel peptidase inhibitors
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US4792452A (en) * 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
EP0362002B1 (fr) 1988-09-01 1995-07-26 Merrell Dow Pharmaceuticals Inc. Inhibiteurs de protease HIV
ZA897514B (en) 1988-10-07 1990-06-27 Merrell Dow Pharma Novel peptidase inhibitors
IT1229491B (it) * 1988-12-28 1991-09-03 Roussel Maestretti S P A Ora R Derivati della 1,2,5,6-tetraidropiridina, loro procedimento di preparazione e loro impiego come sostanze medicinali
TW201303B (fr) 1990-07-05 1993-03-01 Hoffmann La Roche
CA2075154A1 (fr) 1991-08-06 1993-02-07 Neelakantan Balasubramanian Aldehydes peptidiques utilises comme agents antithrombotiques
SE9102462D0 (sv) 1991-08-28 1991-08-28 Astra Ab New isosteric peptides
US5169638A (en) 1991-10-23 1992-12-08 E. R. Squibb & Sons, Inc. Buoyant controlled release powder formulation
CZ333492A3 (en) 1991-11-12 1993-09-15 Lilly Co Eli Dipeptide of l-azetidine-2-carboxylic acids and l-argininaldehyde, process of its preparation and pharmaceutical preparation in which said dipeptide is comprised
SE9103612D0 (sv) 1991-12-04 1991-12-04 Astra Ab New peptide derivatives
US5760235A (en) 1992-03-04 1998-06-02 Gyogyszerkutato Intezet Kft. Anticoagulant peptide derivatives and pharmaceutical compositions containing the same as well as a process for preparation thereof
TW223629B (fr) 1992-03-06 1994-05-11 Hoffmann La Roche
SE9301912D0 (sv) 1993-06-03 1993-06-03 Ab Astra Process for the production of aminoalkylguandines
SE9301916D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
US5780631A (en) 1993-06-03 1998-07-14 Astra Aktiebolag Starting materials in the synthesis of thrombin and kininogenase inhibitors
US6984627B1 (en) 1993-06-03 2006-01-10 Astrazeneca Ab Peptide derivatives
EP0648780A1 (fr) 1993-08-26 1995-04-19 Bristol-Myers Squibb Company Inhibiteurs hétérocycliques de thrombine
TW394760B (en) 1993-09-07 2000-06-21 Hoffmann La Roche Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same
CA2140598C (fr) 1994-01-27 2010-03-09 Masahiro Ohshima Derives de la prolineamide
US5705487A (en) 1994-03-04 1998-01-06 Eli Lilly And Company Antithrombotic agents
ZA951617B (en) 1994-03-04 1997-02-27 Lilly Co Eli Antithrombotic agents.
US5707966A (en) 1994-03-04 1998-01-13 Eli Lilly And Company Antithrombotic agents
US5561146A (en) 1994-06-10 1996-10-01 Bristol-Myers Squibb Company Modified guanidino and amidino thrombin inhibitors
DE4421052A1 (de) 1994-06-17 1995-12-21 Basf Ag Neue Thrombininhibitoren, ihre Herstellung und Verwendung
US5498724A (en) 1994-06-28 1996-03-12 Aktiebolaget Astra Pyrazoleamidine compounds
MX9706069A (es) 1995-02-17 1997-10-31 Basf Ag Nuevos inhibidores de la trombina.
US5710130A (en) 1995-02-27 1998-01-20 Eli Lilly And Company Antithrombotic agents
US6083532A (en) * 1995-03-01 2000-07-04 Duramed Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers and tablet formed therefrom
US5695781A (en) * 1995-03-01 1997-12-09 Hallmark Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers
SA96170106A (ar) 1995-07-06 2005-12-03 أسترا أكتيبولاج مشتقات حامض أميني جديدة
AR005245A1 (es) 1995-12-21 1999-04-28 Astrazeneca Ab Prodrogas de inhibidores de trombina, una formulación farmaceutica que las comprende, el uso de dichas prodrogas para la manufactura de un medicamento y un procedimiento para su preparacion
SE9602263D0 (sv) 1996-06-07 1996-06-07 Astra Ab New amino acid derivatives
WO1997049404A1 (fr) 1996-06-25 1997-12-31 Eli Lilly And Company Agents anticoagulants
SE9602646D0 (sv) 1996-07-04 1996-07-04 Astra Ab Pharmaceutically-useful compounds
DE19632772A1 (de) 1996-08-14 1998-02-19 Basf Ag Neue Benzamidine
AR013084A1 (es) 1997-06-19 2000-12-13 Astrazeneca Ab Derivados de amidino utiles como inhibidores de la trombina, composicion farmaceutica, utilizacion de dichos compuestos para la preparacion demedicamentos y proceso para la preparacion de los compuestos mencionados
IT1297461B1 (it) * 1997-10-29 1999-12-17 Ciocca Maurizio Preparazione di compresse a rilascio controllato a base di complessi tra carragenano e farmaci basici solubili
SE9704543D0 (sv) 1997-12-05 1997-12-05 Astra Ab New compounds
US6251430B1 (en) * 1998-02-04 2001-06-26 Guohua Zhang Water insoluble polymer based sustained release formulation
US6174913B1 (en) 1998-06-05 2001-01-16 The University Of North Carolina At Chapel Hill Naphtho- and dihydrobenzo-thiophene derivatives as cytotoxic antitumor agents
SE9802938D0 (sv) 1998-09-01 1998-09-01 Astra Ab Improved stability for injection solutions
SE9802974D0 (sv) 1998-09-03 1998-09-03 Astra Ab New crystalline forms
SE9802973D0 (sv) 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
AU758178B2 (en) * 1998-09-04 2003-03-20 Scios Inc. Hydrogel compositions for the controlled release administration of growth factors
SE9804313D0 (sv) 1998-12-14 1998-12-14 Astra Ab New compounds
TR200102037T2 (tr) 1999-01-13 2001-10-22 Astrazeneca Ab Yeni amidinobenzilamin türevleri ve trombin engelleyiciler olarak kullanılmaları.
SE9902550D0 (sv) 1999-07-02 1999-07-02 Astra Ab New crystalline forms
US8084258B2 (en) * 1999-07-12 2011-12-27 University Of Basel Manipulation of tissue of organ type using the notch pathway
SE0001803D0 (sv) 2000-05-16 2000-05-16 Astrazeneca Ab New compounds i
US6433186B1 (en) 2000-08-16 2002-08-13 Astrazeneca Ab Amidino derivatives and their use as thormbin inhibitors
AR035216A1 (es) 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
SE0102921D0 (sv) 2001-08-30 2001-08-30 Astrazeneca Ab Pharmaceutically useful compounds
US7129233B2 (en) 2000-12-01 2006-10-31 Astrazeneca Ab Mandelic acid derivatives and their use as thrombin inhibitors
US6287599B1 (en) 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
US6811794B2 (en) 2001-12-20 2004-11-02 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
SE0201658D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab Immediate release pharmaceutical formulation
SE0201661D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab New salts
SE0201659D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab Modified release pharmaceutical formulation
US7781424B2 (en) 2003-05-27 2010-08-24 Astrazeneca Ab Modified release pharmaceutical formulation
SE0303220D0 (sv) 2003-11-28 2003-11-28 Astrazeneca Ab New process
GB0503672D0 (en) 2005-02-23 2005-03-30 Astrazeneca Ab New process
GB0510546D0 (en) 2005-05-24 2005-06-29 Astrazeneca Ab New process
TW200827336A (en) 2006-12-06 2008-07-01 Astrazeneca Ab New crystalline forms

Also Published As

Publication number Publication date
IL159217A (en) 2009-02-11
DE60208369T2 (de) 2006-08-24
ES2254699T3 (es) 2006-06-16
CZ20033491A3 (en) 2004-03-17
US7700582B2 (en) 2010-04-20
UA77959C2 (en) 2007-02-15
EP1401502B1 (fr) 2005-12-28
BR0210489A (pt) 2004-06-22
ATE314093T1 (de) 2006-01-15
HUP0400850A2 (hu) 2004-08-30
IS2347B (is) 2008-03-15
JP2005501024A (ja) 2005-01-13
CN1518462A (zh) 2004-08-04
US20040242536A1 (en) 2004-12-02
KR20040011542A (ko) 2004-02-05
PL366432A1 (en) 2005-01-24
ZA200309316B (en) 2005-02-28
RU2003136155A (ru) 2005-05-20
NZ530086A (en) 2005-09-30
MXPA03011546A (es) 2004-03-19
SK286238B6 (sk) 2008-06-06
IS7081A (is) 2003-12-16
DE60208369D1 (de) 2006-02-02
HUP0400850A3 (en) 2010-10-28
AU2002345463B2 (en) 2007-08-30
MY130332A (en) 2007-06-29
EE200400028A (et) 2004-04-15
IL159217A0 (en) 2004-06-01
CA2450449A1 (fr) 2003-01-03
CO5550466A2 (es) 2005-08-31
RU2323006C2 (ru) 2008-04-27
CZ299859B6 (cs) 2008-12-17
SK15912003A3 (sk) 2004-05-04
EP1401502A1 (fr) 2004-03-31
NO20035627D0 (no) 2003-12-15
SI1401502T1 (sl) 2006-06-30
AR034517A1 (es) 2004-02-25
BG108516A (en) 2004-12-30
WO2003000293A1 (fr) 2003-01-03

Similar Documents

Publication Publication Date Title
DK1401502T3 (da) Farmaceutisk formulering, der omfatter iota-carrageenan og mindst én neutral geldannende polymer
NO20052855D0 (no) Fosfonoksykinazolinderivater og farmasoytisk anvendelse derav.
ITTO20010005A1 (it) Formulazione farmaceutica.
DK2287204T3 (da) Vandopløslige jern-kulhydrat-komplekser, fremstilling deraf og læge-midler, der indeholder disse
NO20012567D0 (no) Azepinoindolderivater, fremstilling og anvendelse derav
NO20033384L (no) Farmasoytisk formulering
DK1572728T3 (da) Polymerkonjugater med nedsat antigenicitet, fremgangsmåder til fremstilling og anvendelser deraf
NO20042084L (no) 6-hydroksyisoflavoner, derivater og legemidler som omfatter disse
NO20014963D0 (no) Cycloalkyl-substituerte benzimidazoler, samt fremstilling og anvendelse derav
NO20033785L (no) Farmasöytisk formulering
NO20051983D0 (no) 3-fenyl-substituert pyridoindolon, fremstilling derav og terapeutisk anvendelse derav.
EE200300311A (et) Ftalasinoon-piperidinoderivaadid, nende kasutamine ja ravim
DK1095025T3 (da) Benzimidazoler, deres fremstilling og deres anvendelse som lægemidler
IS7491A (is) Benzoxazínon-afleidd efnasambönd, framleiðsla þeirra og notkun sem lyf
DK1513835T3 (da) Piperazinylacylpiperidinderivater, fremstilling og terapeutisk anvendelse heraf
DK1417189T3 (da) Acylaminothiazolderivater, fremstilling og terapeutisk anvendelse heraf
NO20013900D0 (no) Epotilonderivater, fremgangsmate og anvendelse derav som legemiddel
DE60206422D1 (de) Walsh-code-verwaltung in einem drahtlosen kommunikationssystem mit codemultiplex-mehrfachzugriff
IS2487B (is) Asýloxýpýrrólidín afleiður, framleiðsla og meðferðarnotkun þar á
NO20022022L (no) N-guanidinoalkylamider, deres fremstilling, deres anvendelse og farmasöytiske preparater omfattende disse
NO20023144D0 (no) Kompleks omfattende OCIF og polysakkarid
DK1053224T3 (da) Biphenylfulfonylcyanamider, fremgangsmåde til fremstilling deraf og anvendelse deraf som lægemiddel
EP1620490A4 (fr) Poly ((polythioalkyl)esters), leurs applications et leurs derives
NO20034785D0 (no) Farmasöytiske kombinasjoner basert på pyridoindolon-derivater og anticancermidler
IS6403A (is) Nýjar heteróarýl afleiður, framleiðsla þeirra og notkun